Target Price | $13.00 |
Price | $8.62 |
Potential |
50.81%
register free of charge
|
Number of Estimates | 2 |
2 Analysts have issued a price target Eton Pharmaceuticals, Inc. 2025 .
The average Eton Pharmaceuticals, Inc. target price is $13.00.
This is
50.81%
register free of charge
$15.00
74.01%
register free of charge
$11.00
27.61%
register free of charge
|
|
A rating was issued by 2 analysts: 2 Analysts recommend Eton Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Eton Pharmaceuticals, Inc. stock has an average upside potential 2025 of
50.81%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 31.64 | 37.11 |
48.89% | 17.27% | |
EBITDA Margin | -0.92% | -6.20% |
97.00% | 576.44% | |
Net Margin | -3.26% | -12.49% |
92.54% | 283.67% |
2 Analysts have issued a sales forecast Eton Pharmaceuticals, Inc. 2024 . The average Eton Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Eton Pharmaceuticals, Inc. 2024 . The average Eton Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Eton Pharmaceuticals, Inc. 2024 . The average Eton Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.04 | -0.18 |
88.89% | 350.00% | |
P/E | negative | |
EV/Sales | 5.66 |
1 Analysts have issued a Eton Pharmaceuticals, Inc. forecast for earnings per share. The average Eton Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Eton Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Eton Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.